Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment

Summary

Investigators hypothesize that ruxolitinib 1.5% cream is an effective therapy for HS participants through inhibition of inflammatory activity. Investigators aim to: * Demonstrate the clinical efficacy of ruxolitinib 1.5% cream in decreasing the clinical disease activity after 16 weeks of treatment. * Investigate the impact of ruxolitinib 1.5% cream on skin inflammation through translational analyses of skin biopsy samples.

Timeline

Start

2022-10-13

Primary completion

2024-02-23

Completion

2024-02-23

Outcome

Outcome not reported

Stopped: “The PI left the Institution and sponsor decided to close the trial.”

Drugs

Indications